{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:13:15Z","timestamp":1791421995605,"version":"4.3.3"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lanmic.2025.101283","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:37:13Z","timestamp":1771360633000},"page":"101283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7342-2608","authenticated-orcid":false,"given":"Onyema","family":"Ogbuagu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Gaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gorgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier O","family":"Morales-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Workowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Brunetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwad","family":"Mponponsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean E","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A","family":"VanderVeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M","family":"Baeten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Eron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2025.101283_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12981-024-00657-w","article-title":"Association of ART regimen and adherence to viral suppression: an observational study of a clinical population of people with HIV","volume":"21","author":"Manalel","year":"2024","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.lanmic.2025.101283_bib3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/13548506.2014.945601","article-title":"A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy","volume":"20","author":"Claborn","year":"2015","journal-title":"Psychol Health Med"},{"key":"10.1016\/j.lanmic.2025.101283_bib4","doi-asserted-by":"crossref","first-page":"E341","DOI":"10.1503\/cmaj.231498","article-title":"Long-acting injectable antiretroviral therapy for HIV-1 infection in adults","volume":"196","author":"Halani","year":"2024","journal-title":"CMAJ"},{"key":"10.1016\/j.lanmic.2025.101283_bib5","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1007\/s10461-020-02929-8","article-title":"Patient-reported outcomes in ATLAS and FLAIR participants on long-acting regimens of cabotegravir and rilpivirine over 48 weeks","volume":"24","author":"Murray","year":"2020","journal-title":"AIDS Behav"},{"key":"10.1016\/j.lanmic.2025.101283_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2020.106182","article-title":"Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries","volume":"139","author":"de Los Rios","year":"2020","journal-title":"Prev Med"},{"key":"10.1016\/j.lanmic.2025.101283_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12879-025-10546-w","article-title":"Patient preferences for long-acting HIV treatment: a preference heterogeneity assessment","volume":"25","author":"Saldarriaga","year":"2025","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.lanmic.2025.101283_bib8","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2352-3018(22)00291-0","article-title":"Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial","volume":"10","author":"Gupta","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.lanmic.2025.101283_bib9","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","article-title":"Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection","volume":"386","author":"Segal-Maurer","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2025.101283_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","article-title":"Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection","volume":"28","author":"Hraber","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.lanmic.2025.101283_bib13","doi-asserted-by":"crossref","first-page":"911","DOI":"10.3390\/v16060911","article-title":"The use of broadly neutralizing antibodies (bNAbs) in HIV-1 treatment and prevention","volume":"16","author":"Thavarajah","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.lanmic.2025.101283_bib14","article-title":"Phase 2 trial of long-acting cabotegravir and VRC07-523LS for viral suppression in adults with HIV-1: ACTG A5357","author":"Taiwo","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.lanmic.2025.101283_bib15","series-title":"VH3810109 (N6LS) efficacy and safety in adults who are virologically suppressed: the EMBRACE study","author":"Taiwo","year":"2025"},{"key":"10.1016\/j.lanmic.2025.101283_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lanmic.2025.101283_bib17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","article-title":"Prolonged viral suppression with anti-HIV-1 antibody therapy","volume":"606","author":"Gaebler","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.lanmic.2025.101283_bib18","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","article-title":"A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection","volume":"24","author":"Gautam","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2025.101283_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/QAI.0000000000003528","article-title":"Susceptibility screening of HIV-1 viruses to broadly neutralizing antibodies, teropavimab and zinlirvimab, in people with HIV-1 suppressed by antiretroviral therapy","volume":"98","author":"Selzer","year":"2025","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.lanmic.2025.101283_bib20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/infdis\/jiaf159","article-title":"Lenacapavir plus 2 broadly neutralizing antibodies, teropavimab and zinlirvimab, for people with HIV-1 highly susceptible to either teropavimab or zinlirvimab","volume":"231","author":"Eron","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2025.101283_bib21","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3018(23)00293-X","article-title":"Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study","volume":"11","author":"Eron","year":"2024","journal-title":"Lancet HIV"},{"key":"10.1016\/j.lanmic.2025.101283_bib22","series-title":"Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: phase 2 week 26 primary outcome. Oral presentation #151","author":"Ogbuagu","year":"2025"},{"key":"10.1016\/j.lanmic.2025.101283_bib23","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/QAD.0000000000003792","article-title":"HIV-1 envelope diversity and sensitivity to broadly neutralizing antibodies across stages of acute HIV-1 infection","volume":"38","author":"VanderVeen","year":"2024","journal-title":"AIDS"},{"key":"10.1016\/j.lanmic.2025.101283_bib25","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","article-title":"Test-based exact confidence intervals for the difference of two binomial proportions","volume":"55","author":"Chan","year":"1999","journal-title":"Biometrics"},{"key":"10.1016\/j.lanmic.2025.101283_bib26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkab324","article-title":"Long-acting antiretrovirals: a new era for the management and prevention of HIV infection","volume":"77","author":"Thoueille","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.lanmic.2025.101283_bib27","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2025.101283_bib28","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2025.101283_bib29","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","article-title":"Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial","volume":"390","author":"Margolis","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2025.101283_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae560","article-title":"Efficacy, safety, and tolerability of switching from bictegravir\/emtricitabine\/tenofovir alafenamide to dolutegravir\/lamivudine among adults with virologically suppressed HIV: the DYAD study","volume":"11","author":"Rolle","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lanmic.2025.101283_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/QAD.0000000000003088","article-title":"Evaluation of HIV-1 reservoir size and broadly neutralizing antibody susceptibility in acute antiretroviral therapy-treated individuals","volume":"36","author":"Moldt","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.lanmic.2025.101283_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02777-24","article-title":"Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO Registry","volume":"13","author":"Spagnuolo","year":"2025","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.lanmic.2025.101283_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","article-title":"Combination anti-HIV antibodies provide sustained virological suppression","volume":"606","author":"Sneller","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.lanmic.2025.101283_bib34","series-title":"The RIO trial: a randomised placebo-controlled study of 2 LS-bNAbs (3BNC-117-LS & 10\u20131074-LS) in people treated in early HIV","author":"Fidler","year":"2025"},{"key":"10.1016\/j.lanmic.2025.101283_bib35","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.3390\/pharmaceutics15102488","article-title":"Clinical relevance of drug interactions in people living with human immunodeficiency virus on antiretroviral therapy\u2013update 2022: systematic review","volume":"15","author":"Amariles","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524725002113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524725002113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:54:25Z","timestamp":1773186865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524725002113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666524725002113"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2025.101283","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2025.101283","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101283"}}